Skip to content
sellModerate cluster of 710b5-1 plan

Andrew Dudum sold $8.6M of HIMS

Chief Executive Officer at Hims & Hers Health, Inc.. 254,421 shares at an average of $33.87, traded Mar 17, 2025, filed Mar 18, 2025.

Warning score
50
Value
$8.6M
254,421 shares
Holdings after
94,895
-132% from before
From 52-week low
+127%
low $15.27, close $34.69
From 52-week high
-50%
high $68.74, as of Mar 17, 2025

Score components

  • Role
    CEO
    +25
  • Trade size
    $8.6M at market
    +25
  • Share of holdings sold
    Sold 100% of holdings
    +20
  • Cluster
    7 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

HIMSOct 9, 2026 · close 30.92
Since filing Mar 18, 2025: -1.8%SPY +41.5% · excess -43.3%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001773751-25-000101, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 14, 2025MOption exercise
Class A Common Stock10b5-1
+176,311--273,998Mar 18, 2025
Mar 14, 2025FTax withholding
Class A Common Stock10b5-1
-97,551$33.14$3.2M176,447Mar 18, 2025
Mar 17, 2025MOption exercise
Class A Common Stock10b5-1
+17,001$2.43$41k193,448Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-17,001$32.97$560k176,447Mar 18, 2025
Mar 17, 2025MOption exercise
Class A Common Stock10b5-1
+50,000$2.43$122k226,447Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-50,000$35.28$1.8M176,447Mar 18, 2025
Mar 17, 2025MOption exercise
Class A Common Stock10b5-1
+41,667$2.43$101k218,114Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-27,347$33.49$916k190,767Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-14,320$32.91$471k176,447Mar 18, 2025
Mar 17, 2025MOption exercise
Class A Common Stock10b5-1
+16,667$2.43$41k193,114Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-16,667$32.96$549k176,447Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stock10b5-1
-2,792$33.01$92k173,655Mar 18, 2025
Mar 18, 2025SOpen-market sale
Class A Common Stock10b5-1
-57,713$33.75$1.9M115,942Mar 18, 2025
Mar 18, 2025SOpen-market sale
Class A Common Stock10b5-1
-21,047$34.13$718k94,895Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stockindirect: Held by Trustee of Dudum Family Community Property Trust10b5-1
-40,447$33.55$1.4M387,349Mar 18, 2025
Mar 17, 2025SOpen-market sale
Class A Common Stockindirect: Held by Trustee of Dudum Family Community Property Trust10b5-1
-7,087$34.15$242k380,262Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-35,447$0.00$0283,572Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-35,242$0.00$0140,968Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-74,530$0.00$0894,358Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-7,330$0.00$00Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-108$0.00$00Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-3,576$0.00$00Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-1,789$0.00$00Mar 18, 2025
Mar 14, 2025MOption exercise
Restricted Stock Unitderivative10b5-1
-18,289$0.00$00Mar 18, 2025
Mar 17, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-17,001$0.00$0136,012Mar 18, 2025
Mar 17, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-50,000$0.00$01,248,067Mar 18, 2025
Mar 17, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-41,667$0.00$01,206,400Mar 18, 2025
Mar 17, 2025MOption exercise
Stock Option (right to buy)derivative10b5-1
-16,667$0.00$01,189,733Mar 18, 2025

Related signals

Other insiders at Hims & Hers Health, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
13Weak
HIMSsell 210b5-1
Hims & Hers Health, Inc.
Soleil Boughton
Chief Legal Officer
$101k
3,461 shares
-1%
17Weak
HIMSsell 210b5-1
Hims & Hers Health, Inc.
Oluyemi Okupe
Chief Financial Officer
$59k
2,000 shares
-1%
30Weak
HIMSsell 410b5-1
Hims & Hers Health, Inc.
Oluyemi Okupe
Chief Financial Officer
$877k
29,277 shares
-11%
32Weak
HIMSsell 410b5-1
Hims & Hers Health, Inc.
Oluyemi Okupe
Chief Financial Officer
$355k
12,313 shares
-5%
21Weak
HIMSsell 410b5-1
Hims & Hers Health, Inc.
Soleil Boughton
Chief Legal Officer
$174k
6,236 shares
-2%
31Weak
HIMSsell 410b5-1
Hims & Hers Health, Inc.
Michael Chi
Chief Operating Officer
$398k
14,027 shares
-3%
23Weak
HIMSsell 410b5-1
Hims & Hers Health, Inc.
Mohamed Elshenawy
CTO
$226k
7,954 shares
-4%
20Weak
HIMSsell 310b5-1
Hims & Hers Health, Inc.
Soleil Boughton
Chief Legal Officer
$98k
3,458 shares
-1%
52Moderate
HIMSsell 510b5-1
Hims & Hers Health, Inc.
Oluyemi Okupe
Chief Financial Officer
$1.1M
23,107 shares
-27%
33Weak
HIMSsell 510b5-1
Hims & Hers Health, Inc.
Irene Becklund
PAO
$507k
8,485 shares
-92%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Andrew Dudum sold $8.6M of HIMS | InsiderTell